4'-hydroxy-γ-oxo(1,1'-biphenyl)-4-butanoic acid | 74277-78-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4'-hydroxy-γ-oxo(1,1'-biphenyl)-4-butanoic acid
• 英文别名: 4-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-4-oxobutanoic acid；p-hydroxyfenbufen；4-(4'-hydroxy-biphenyl-4-yl)-4-oxo-butyric acid；4-(4'-Hydroxy-biphenyl-4-yl)-4-oxo-buttersaeure；4-(4'-hydroxybiphenyl-4-yl)-4-oxobutanoic acid；4'-Hydroxy-gamma-oxo-4-biphenylbutyric acid；4-[4-(4-hydroxyphenyl)phenyl]-4-oxobutanoic acid
• CAS: 74277-78-4
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.285
• InChiKey: LJTFZTUQXHWXND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(4-p-Methoxyphenylbenzoyl)propionsaeure 在 氢碘酸 作用下， 生成 4'-hydroxy-γ-oxo(1,1'-biphenyl)-4-butanoic acid
  参考文献：
  名称：

  Synthetic Choleretics. II. Phenol Derivatives¹

  摘要：

  DOI：

  10.1021/ja01106a014

文献信息

• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid
  申请人：American Cyanamid Company

  公开号：US04247466A1

  公开（公告）日：1981-01-27

  Compounds of lactone metabolites of 3-(4-Biphenylylcarbonyl)propionic acid useful as anti-inflammatory and anti-platelet aggregation agents.

  乳酮代谢物的化合物，可用作抗炎和抗血小板聚集剂，其中乳酸代谢物是3-（4-联苯基羰基）丙酸。
• Antiinflammation Derived Suzuki-Coupled Fenbufens as COX-2 Inhibitors: Minilibrary Construction and Bioassay
  作者：Shiou-Shiow Farn、Yen-Buo Lai、Kuo-Fong Hua、Hsiang-Ping Chen、Tzu-Yi Yu、Sheng-Nan Lo、Li-Hsin Shen、Rong-Jiun Sheu、Chung-Shan Yu

  DOI：10.3390/molecules27092850

  日期：——

  celecoxib. The most COX-2 selective and bioactive disubstituted compound encompasses one electron-withdrawing methyl and one electron-donating fluoro groups in one arene. COX-2 is selective but not COX-2 to bioactive compounds that contain both two electron-withdrawing groups; disubstituted analogs with both resonance-formable electron-donating dihydroxy groups display high COX-2 activity but inferior COX-2

  通过 Suzuki Miyara 偶联制备了一个包含 18 种化合物的小型 fenbufen 文库。五步制备可提供 9-17% 的联苯化合物总产率。这些芬布芬类似物对 IL-1 释放的活性不显着，并且显着抑制环氧合酶 2。对氨基和对-羟基单取代基显示出最显着的 COX-2 抑制作用，尤其是后者显示出与塞来昔布相当的活性。最具 COX-2 选择性和生物活性的二取代化合物在一个芳烃中包含一个吸电子甲基和一个给电子氟基团。COX-2 对同时含有两个吸电子基团的生物活性化合物具有选择性，但对 COX-2 没有；具有可共振形成的给电子二羟基的二取代类似物表现出高 COX-2 活性，但 COX-2 选择性较差。对三种 COX-2 活性物质（对氟、对羟基和对氨基）进行计算机模拟和建模，芬布芬与 COX-2 的对接比 COX-1 更好。p最稳定通过理论模拟预测的具有COX-2的-羟基芬布芬与实验产生的其显着的COX-2抑制一致。
• US4247466A
  申请人：——

  公开号：US4247466A

  公开（公告）日：1981-01-27